Personalis, Inc
Personalis is a biotech company transforming cancer management through personalized testing, providing insights that help in early detection, targeted therapy selection, and biomarker strategy for drug development. They are based in Fremont, California, and adopt a hybrid work model.
Headquarters
Fremont, California, United States
Company Size
201-500 employees
Founded
2011
Personalis is a genomics company transforming the active management of cancer through advanced ctDNA (circulating tumor DNA) technologies. Their solutions enable highly sensitive liquid biopsy testing, supporting applications from molecular residual disease (MRD) detection to therapy selection. Personalis serves oncology-focused customers seeking actionable cancer insights through cutting-edge sequencing and bioinformatics.
Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of "Moderate Buy" from Analysts
1 day ago
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
2 weeks ago
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
1 month ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Personalis, Inc.
With 42% ownership, Personalis, Inc. (NASDAQ:PSNL) has piqued the interest of institutional investors
Sep 18, 2025
Research Technician-Radiation Oncology (Willers Lab)
Brigham and Women's Hospital
Internship - Bioinformatics
Alamar Biosciences
Director of Bioinformatics and Machine Learning
Natera
Computational biologist/Expert I Data Science (80-100%) (Junior position)
Diversity Employment
Manager, Clinical Operations
Nuvalent, Inc.
Senior Director Diagnostic Assays/Cancer Biomarker Development
AstraZeneca